The invention relates to the use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of *S. pneumoniae* for preventing or treating a *S. pneumoniae* infection, their use for the preparation of a vaccine for the preventive treatment of a *S. pneumoniae* infection, compositions comprising said proteins of *S. pneumoniae* or functional fragments thereof, vaccines comprising said proteins or functional fragment thereof, and to a method for *in vivo* immune protection.
Title: Combination vaccine for *Streptococcus*

The invention relates to the field of medicine, more especially to the field of vaccines against bacterial infections, more particularly the genus *Streptococcus*, more particularly the species *Streptococcus pneumoniae*.

*Streptococcus pneumoniae* (pneumococcus, *S. pneumoniae*) is an important pathogen, which causes significant morbidity and mortality throughout the world. *S. pneumoniae* is a major cause of invasive diseases such as meningitis, bacteremia, and pneumonia, as well as non-invasive diseases like acute otitis media and sinusitis (i). In young children, the pneumococcus is often part of the normal nasopharyngeal flora. Especially during the first two years of life, children are colonised with novel strains of pneumococci. Children colonised with *S. pneumoniae* develop more often acute otitis media than children who are not colonised (ii, iii, iv).

The precise molecular mechanisms through which the pneumococcus invades and damages host tissues are not fully understood. For many years, the polysaccharide capsule has been recognised in the art as the major virulence factor and, consequently, an important vaccine candidate (for review, see v, vi). The current pneumococcal vaccine strategies focus on the use of conjugates, in which a limited number of different capsular polysaccharides are linked to a carrier protein (vii,viii). Although the results of early trials look promising, problems still arise since large-scale vaccination over time generally leads to a shift in serotype distribution towards capsular types that are poorly immunogenic or not included in the vaccine. Such a shift may be enhanced by the frequent horizontal exchange of capsular genes, as described by several investigators (ix, x, xi).

Over the last few years, much attention has been focused on the role of pneumococcal proteins in pathogenesis and protection. Proteins that are involved in the pathogenesis of infections by *S. pneumoniae* are considered to be interesting components for future conjugate vaccines. Such proteins are able to switch the immune response against the polysaccharides present in the vaccine from T-cell independent to T-cell dependent, through which the antibody response towards the polysaccharides may be increased and a memory response will be provided. In
addition, such proteins should provide protection against colonisation and infection
with *S. pneumoniae* strains whose capsular polysaccharides are not included in the
vaccine.

The protective abilities of various (virulence) proteins have been investigated
previously. Immunisation of pneumolysin (xii), pneumococcal surface protein A (PspA)
(xiii, χi,χv) pneumococcal surface adhesin A (PsaA) (xvi), and neuraminidase (xvii)
clearly confer protection in animals.

In the literature various polynucleotides of *S. pneumoniae* and polypeptides
predicted to be encoded by said nucleotides have been reported and the use of these
compounds in vaccines and medicinal preparation has been contemplated, for instance
in WO 97/37026, WO 00/06737 and WO 98/18930. These publications however, do not
identify any functional protein let alone a vaccine based on a functional protein. These
publications are further silent in respect of proteins that when used in vaccines are
able to elicit an immuneresponse let alone that they are able to elicit any protective
activity.

Currently available are a 23-valent polysaccharide vaccine (Pneumovax 23™,
Merck, USA) and a 7-valent pneumococcal conjugate vaccine (Prevenar™, Wyeth,
USA) giving good immune protection. However, there are limitations with these
vaccines. Both polysaccharide and conjugate vaccines only protect against the vaccine
type serotypes, allowing replacement of non-vaccine serotypes to occur. This serotype
replacement and subsequent disease has emphasized the need for alternative vaccine
strategies.

The world is in need of an effective, low-cost vaccine that would ideally provide
immunologic protection against all pneumococcal serotypes, pneumococcal
colonization and invasive disease. The vaccine would be immunogenic in all age
groups and elicit a boostable response.

The present invention identifies a multi-component protein vaccine which
encompasses several conserved pneumococcal proteins which have shown some degree
of protection in murine models as novel vaccine candidates.

It has now been found that a combination of two proteins of *S. pneumoniae* can
be used in the preparation of a vaccine against micro-organisms and especially *S.
*pnemoniae. These proteins are amongst a large group of proteins that was detected
during a genome-wide negative selection screen for bacterial factors contributing to

The invention accordingly relates to an immunological composition, a vaccine or medical preparation comprising the proteins SP1298 and SP2205 and/or fragments thereof and/or homologous and/or functionally homologous proteins and/or fragments thereof for the treatment of microbial infections and especially of S. pneumoniae infections and for the generation of antibodies in an immunised or vaccinated vertebrate host and which expresses opsonophagocytic activity against S. pneumoniae and infections thereof. The invention also relates to the use of these proteins or fragments thereof for the preparation of a vaccine for the treatment of a S. pneumoniae infection and/or colonisation and to the use of these proteins or fragments thereof or recombinant or synthetic proteins or fragments or functionally homologous proteins or fragments thereof as a carrier for inducing prophylactic protection against other micro-organisms including viruses.

In this description and the appending claims treatment encompasses and generally is the prophylaxis of infections.

The term "functional fragment" refers to a shortened version of the protein, which is a functional variant or functional derivative. A "functional variant" or a "functional derivative" of a protein is a protein the amino acid sequence of which can be derived from the amino acid sequence of the original protein by the substitution, deletion and/or addition of one or more amino acid residues in a way that, in spite of the change in the amino acid sequence, the functional variant retains at least a part of at least one of the biological activities of the original protein that is detectable for a person skilled in the art. A functional variant is generally at least 60% homologous (preferably the amino acid sequence is at least 60% identical), advantageously at least 70% homologous and even more advantageously at least 80 or 90% homologous to the protein from which it can be derived. A functional variant may also be any functional part of a protein; the function in the present case being particularly but not exclusively essential activity for nasopharyngeal colonization or infection of middle ear, lung, blood and/or meningi. "Functional" as used herein means functional in Streptococcus pneumoniae bacteria and capable of eliciting antibodies which give protection against disease caused by said bacteria.
The expression "conservative substitutions" as used with respect to amino acids relates to the substitution of a given amino acid by an amino acid having physicochemical characteristics in the same class. Thus where an amino acid of the SP1298 and/or SP2205 proteins has a hydrophobic characterising group, a conservative substitution replaces it by another amino acid also having a hydrophobic characterising group; other such classes are those where the characterising group is hydrophilic, cationic, anionic or contains a thiol or thioether. Such substitutions are well known to those of ordinary skill in the art, i.e. see US 5,380,712. Conservative amino acid substitutions may be made, for example within the group of aliphatic non-polar amino acids (Gly, Ala, Pro, He, Leu, Val), the group of polar uncharged amino acids (Cys, Ser, Thr, Met, Asn, Gin), the group of polar charged amino acids (Asp, Glu, Lys, Arg) or the group of aromatic amino acids (His, Phe, Tyr, Trp).

The term "immunogenic part" includes reference to any part of a protein especially SP1298 and/or SP2205, or a functional homologue or functional fragment thereof, which is capable of eliciting an immune response in a mammal. Said immunogenic part preferably corresponds to an antigenic determinant of said pathogen.

As used herein, the term "antigen" refers to a molecule capable of being bound by an antibody or a T cell receptor (TCR) if presented by molecules of the major histocompatibility complex (MHC). The term "antigen", as used herein, also encompasses T-cell epitopes. A T-cell epitope is recognized by a T-cell receptor in the context of a MHC class I, present on all cells of the body except erythrocytes, or class II, present on immune cells and in particular antigen presenting cells. This recognition event leads to activation of T-cells and subsequent effector mechanisms such as proliferation of the T-cells, cytokine secretion, perforin secretion etc. An antigen is additionally capable of being recognized by the immune system and/or being capable of inducing a humoral immune response and/or cellular immune response leading to the activation of B- and/or T-lymphocytes. This may, however, require that, at least in certain cases, the antigen contains or is linked to a T-Helper cell epitope and is given in adjuvant. An antigen can have one or more epitopes (B- and T-epitopes). The specific reaction referred to above is meant to indicate that the antigen will preferably react, typically in a highly selective manner, with its corresponding antibody or TCR and not with the multitude of other antibodies or
TCRs which may be evoked by other antigens. Antigens as used herein may also be mixtures of several individual antigens. Antigens, as used herein, include infectious disease antigens, more especially antigens of *Streptococcus pneumoniae*, more preferable antigens derived from the SP1298 and/or SP2205 proteins and fragments and derivatives thereof.

As used herein, the term "antigenic determinant" is meant to refer to that portion of an antigen that is specifically recognized by either B- or T-lymphocytes. B-lymphocytes respond to foreign antigenic determinants via antibody production, whereas T-lymphocytes are the mediator of cellular immunity. Thus, antigenic determinants or epitopes are those parts of an antigen that are recognized by antibodies, or in the context of an MHC, by T-cell receptors. An antigenic determinant may contain one or more epitopes.

The term "prophylactic or therapeutic treatment of an infection by *Streptococcus pneumoniae*" or "prophylactic or therapeutic treatment of a pneumococcal infection" refers to both prophylactic or therapeutic treatments wherein virulence of the pathogen is blocked or diminished, but also to treatments wherein antibodies against the SP1298 and/or SP2205 proteins recognize the bacteria and will protect the host against infection, either directly through immune clearance, or indirectly by blocking the activity of the protein, thereby inhibiting the growth of the bacteria. Also, the term refers to blocking the function of the SP1298 and/or SP2205 proteins *in vivo* thereby reducing the adhesion abilities of the pathogen with a concomitant reduction in colonization and invasion capabilities. The term thus includes inducing immune responses in subjects using vaccine formulations of the invention, as well as inhibiting growth of the pathogen *in vivo* by using antibodies of the present invention as an active compound in a pharmaceutical composition administered to the subject. Also included is the inhibition of the virulence and/or growth of the bacteria by treatment with antibiotics.

The term "antibody" refers to molecules which are capable of binding an epitope or antigenic determinant and includes reference to antigen binding forms of antibodies (e. g., Fab, F(ab)2). The term "antibody" frequently refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). However, while various antibody fragments can be defined in terms of the digestion of
an intact antibody, one of skill will appreciate that such fragments may be
synthesized de novo either chemically or by utilizing recombinant DNA methodology.
Thus, the term antibody, as used herein, also includes antibody fragments such as
single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions
from different species), humanized antibodies (i.e., comprising a complementarity
determining region (CDR) from a non-human source) and heteroconjugate antibodies
(e.g., bispecific antibodies). The antibody can be monoclonal or polyclonal and can be
prepared by techniques that are well known in the art such as immunization of a host
and collection of sera (polyclonal) (see, e.g., Parker, Radioimmunoassay of Biologically
hybrid cell lines and collecting the secreted protein (monoclonal) (see, e.g., Kohler et al
in Nature 256, 495-497 (1975) and Eur. J. Immunol. 6, 511-519 (1976); by Milstein et
al. Nature 266, 550-552 (1977); and by Walsh Nature 266, 495 (1977)) or by cloning
and expressing nucleotide sequences or mutagenized versions thereof coding at least
for the amino acid sequences required for specific binding of natural antibodies.
Antibodies may include a complete immunoglobulin or fragment thereof, which
immunoglobulins include the various classes and isotypes, such as IgA, IgD, IgE,
IgGl, IgG2a, IgG2b and IgG3, IgM, etc. Fragments thereof may include Fab, Fv and
F(ab')2, Fab', and the like. In addition, aggregates, polymers, and conjugates of
immunoglobulins or their fragments can be used where appropriate so long as binding
affinity for a particular molecule is maintained.

As used herein, the term "monoclonal antibody" refers to an antibody
composition having a homogeneous antibody population. The term is not limited
regarding the species or source of the antibody, nor is it intended to be limited by the
manner in which it is made. The term encompasses whole immunoglobulins as well as
fragments such as Fab, F(ab')2, Fv, and others, such as CDR fragments, which retain
the antigen binding function of the antibody. Monoclonal antibodies of any
mammalian species can be used in this invention. In practice, however, the antibodies
will typically be of rat or murine origin because of the availability of rat or murine cell
lines for use in making the required hybrid cell lines or hybridomas to produce
monoclonal antibodies.
As used herein, the term "humanized monoclonal antibodies" means that at least a portion of the exposed amino acids in the framework regions of the antibody (or fragment), which do not match with the corresponding amino acids in the most homologous human counterparts, are changed, such as by site directed mutagenesis of the DNA encoding the antibody. Because these exposed amino acids are on the surface of the molecule, this technique is called "resurfacing." Moreover, because the amino acids on the surface of the molecule are the ones most likely to give rise to an immune response, this resurfacing decreases the immunogenicity of the monoclonal antibody when administered to a species whose cell line was not used to generate the antibody, such as a human. The term "humanized monoclonal antibody" also includes chimeric antibody wherein the light and heavy variable regions of a monoclonal antibody generated by a hybridoma from a non-human cell line are each attached, via recombinant technology, to one human light chain constant region and at least one heavy chain constant region, respectively. The preparation of such chimeric (i.e., humanized) antibodies are well known in the art.

The term "specifically recognizing", includes reference to a binding reaction between an antibody and a protein having an epitope recognized by the antigen binding site of the antibody. This binding reaction is determinative of the presence of a protein having the recognized epitope amongst the presence of a heterogeneous population of proteins and other biologies. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the SP1298 and/or SP2205 proteins of the present invention can be selected to obtain antibodies specifically recognizing said proteins. The proteins used as immunogens can be in native conformation or denatured so as to provide a linear epitope. A variety of immunoassay formats may be used to select antibodies specifically recognizing a particular protein (or other analyte). For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions that can be used to determine selective reactivity.

A "subject" as referred to herein is meant to include mammals and other animals, wherein mammals include for example, humans, apes, monkeys, horses,
cattle, pigs, goats, dogs, cats, rats, mice, and sheep. The term "non-human animal" is meant to disclaim humans. Preferably in the present invention, the subject is a human, more preferably a child or an elderly person.

The proteins SP1298 and SP2205 have an amino acid sequence as provided in Fig. 1. The proteins SP1298 and SP2205 of the present invention have been identified by genomic array footprinting (GAF), which is a high-throughput method to identify conditionally essential genes in *Streptococcus pneumoniae* by using a combination of random transposon mutagenesis and microarray technology (see Bijlsma, J.J.E. et al., 2007, Appl. Environm. Microbiol. 73(5):1514-1524, and WO 2008/127094). GAF detects the transposon insertion sites in a mutant library by amplifying and labelling the chromosomal DNA adjacent to the transposon and subsequent hybridisation of these probes to a microarray. Identification of transposon insertion sites in mutants that have disappeared from the library due to selection, which represent conditionally essential genes, is achieved by differential hybridisation of the probes generated from the library grown under two conditions to an array. For the detection of essential genes for nasopharyngeal colonization and/or dissemination to and/or survival in the blood, mutant libraries of *Streptococcus pneumoniae* were used to infect mice in a murine pneumonia model of infection. For specific detection of essential genes for nasopharyngeal colonization, mutant libraries of *Streptococcus pneumoniae* were used to infect mice in a murine colonization model of infection. For specific detection of essential genes for survival in the blood, mutant libraries of *Streptococcus pneumoniae* were used to infect mice in a murine bacteraemia model of infection. After challenge mutants were identified that had disappeared from the nasopharyngeal lavage and/or blood samples taken from the mice, and the disrupted genes of these mutants were identified. SP1298 and SP2205 were amongst the proteins that have been identified as being candidates for vaccine development.

It has now surprisingly been found that a combination of both proteins is more effective in developing an immunologic response than the individual proteins.

In a preferred embodiment of the invention the protein or fragment(s) thereof used in the preparation of the vaccine, is SP1298 or a (functional) homologous
fragment thereof of *S. pneumoniae*. Additionally, the vaccine may contain SP2205 or any other immunogenic protein.

In an alternative embodiment of the invention the protein or fragment(s) thereof used in the preparation of the vaccine, is SP2205 or a (functional) homologous fragment thereof of *S. pneumoniae*. Additionally, the vaccine may contain SP1298 or any other immunogenic protein.

The most preferred embodiment of the invention is where both SP1298 and SP2205 or functional fragment(s) thereof or homologous proteins or functional fragments thereof are used in the preparation of a vaccine. Additionally such a vaccine may comprise other immunogenic proteins, such as any of the proteins listed in WO 2008/127094 and PCT/NL2009/050600.

It is likewise possible to employ a fragment of SP1298 and/or SP2205 for the preparation of a vaccine. A fragment is a polypeptide with an amino acid sequence which is functionally similar to the corresponding section of the protein. A preferred fragment is an oligopeptide that contains one of the characterising parts or active domains of the protein. The proteins or the functional fragments thereof can be obtained by recombinant techniques or by chemical synthesis. Synthetic oligopeptides based on or derived from SP1298 and/or SP2205 can for instance be obtained by conventional pepscan technology. A person of skill in the art can easily prepare fragments or homologous proteins of both SP1298 and/or SP2205. Further, the applicability of these fragments or homologous proteins for providing an immunological response to *S. pneumoniae* infection can be readily tested by the skilled person by e.g. performing experiments such as described in the experimental section below.

The proteins or (functional) fragments that are used in the preparation of the vaccine can be partially purified proteins, purified proteins or fragments of SP1298 and/or SP2205.

In order to obtain a vaccine that can be administered, the protein or proteins or fragments are brought into a form that is suitable for this purpose. To this end, the protein(s) can be conjugated with a carrier protein. Carrier proteins that can be used in this invention are in general conventional carriers and as such are well known in
the art. The vaccine can likewise also comprise adjuvants and other additional components to further ensure the proper functioning of the vaccine. These additional components are generally known by the skilled man.

In a preferred embodiment of the invention, the composition comprising the protein(s) or the fragment(s) are therefore combined with an adjuvant and/or a carrier. From this composition a vaccine is prepared which is used in the preventive vaccination against *S. pneumoniae*.

The invention further provides for a method for the preparation of a vaccine against *S. pneumoniae*. The method comprises the steps of preparing or isolating the protein or the fragment or homologue or functional homologue of the protein or fragment, determining the immunogenic response by raising antibodies against the protein or the fragment or homologue or functional homologue of the protein or fragment and testing the antibodies for activity. The method according to the invention also encompasses the recombinant or synthetic production of the protein or the fragment or homologue or functional homologue of the protein or fragment and the subsequent steps to the preparation of the vaccine.

The vaccine antigens of this invention are administered at a concentration that is therapeutically effective to prevent or treat infections by *Streptococcus pneumoniae*. To accomplish this goal, the vaccines may be formulated using a variety of acceptable excipients known in the art. Typically, the vaccines are administered by injection, either intravenously or intraperitoneally. Methods to accomplish this administration are known to those of ordinary skill in the art.

Preferably the vaccine contains at least 5-150 μg of antigenic mass per dose, more preferably 50-100 μg and most preferably 80 μg per dose. The antigenic mass being the mass of the antigen protein. Vaccines according to the present invention with an antigenic mass up to 275 μg per dose could even be prepared, and such vaccines may still not elicit local reactions at the injection site. Of course even more micrograms of antigen can be put in a vaccine dose of a vaccine according to the invention, but if the protection obtained with the vaccine is not improved with a higher dose the increase in antigenic load only results in the vaccine being more expensive than necessary. In addition an increasing dose of antigen may eventually lead to unacceptable local reactions at the injection site, which should be avoided.
A vaccine according to the invention may contain a (partially) purified or recombinant SP1298 and/or SP2205 protein or a functional fragment thereof, wherein said recombinant protein is preferably produced by way of expression from a expression vector in suitable host cells, said expression vector containing the gene sequence or an immunogenic part thereof under control of a suitable promoter. Several suitable expression systems are known in the art and may be used in a method to prepare a vaccine according to the invention.

A vaccine according to the invention may further comprise a suitable adjuvant. Many adjuvant systems are known in the art, for example commonly used oil in water adjuvant systems. Any suitable oil may be used, for example a mineral oil known in the art for use in adjuvants. The oil phase may also contain a suitable mixture of different oils, either mineral or non-mineral. Suitable adjuvants may also comprise vitamin E, optionally mixed with one or more oils. The water phase of an oil in water adjuvated vaccine will contain the antigenic material. Suitable formulations will usually comprise from about 25-60% oil phase (40-75% water phase). Examples of suitable formulations may comprise 30% water phase and 70% oil phase or 50% of each. Especially preferred is a non-recombinant lactococcal-based vaccine displaying the herein mentioned pneumococcal antigenic proteins or fragments thereof. The lactococcal-derived bacterial shaped particles are non-living and are designated Gram-positive Enhancer Matrix (GEM) particles (Van Roosmalen, M.L. et al., 2006, Methods 38:144-149). These GEM particles are deprived of surface proteins and the intracellular content is largely degraded (Bosma, T. et al., 2006, Appl. Environ. Microbiol. 72:880-889). The GEM particles can be used as anchoring and delivery vehicle for pneumococcal proteins (see Audouy, S.A.L. et al., 2007, Vaccine 25(13):2497).

The vaccine formulations of the present invention may be used in prophylactic methods of the invention by immunizing a subject by introducing said formulations into said subject subcutaneously, intramuscularly, intranasally, intradermally, intravenously, transdermally, transmucosally, orally, or directly into a lymph node. In another embodiment, the composition may be applied locally, near a local pathogen reservoir against which one would like to vaccinate.
The present invention further provides a method for the manufacture of a vaccine intended for the protection of a subject against pneumococcal infection, wherein said vaccine is combined with a pharmaceutically acceptable diluent, carrier, excipient or adjuvant therefore, such that a formulation is provided which can provide a dose of at least 20 μg protein in a single administration event.

A vaccine (prepared by a method) according to the invention can be used in a method to protect a subject against pneumococcal infection.

To provide adequate protection the vaccine is preferably administered in a 2 shot vaccination regimen, whereby the first shot (priming vaccination) and second shot (boosting vaccination) are given to the subject with an interval of about 3 weeks. In this way the subject will have obtained full protection against pneumococcal infection. The vaccination is very favourable for young children.

Description of the Figures:

Figure 1: Amino acid (AA) sequences of SP1298 (311 AA; top) and SP2205 (657 AA; bottom). Conservation of the DHH consensus domain (pfam01368) in both proteins is indicated by bold font, and conservation of the DHH-associated (DHHAI) consensus domain (pfam02272) by italics. The transmembrane domains (first 50 AA) removed for expression of SP2205 are indicated by small (i.e. non capital) characters.

Figure 2: Contribution of the proteins to adherence to human pharyngeal epithelial Detroit 562 cells. Left bar: wild type *S. pneumoniae*, middle bar SP1298 mutant and right bar SP2205 mutant. Adherence is expressed relative to wild-type, and the different strain backgrounds used are indicated below the x-axis.

Figure 3: Bacterial load in colonization model single infection and co-infection experiments in mice.

Figure 4: Bacterial load in pneumonia model single infection and co-infection experiments in mice. Concentration in lung tissue, lung lavage (BAL) and blood.

Figure 5: Bacterial load in bacteremia model single infection and co-infection experiments in mice.

Figure 6: Bacterial load after vaccination with one or both recombinant proteins compared with positive controls Prevenar™ and PspA and with negative control (alum) after challenge with TIGR4 wild-type.
EXAMPLES
MATERIALS AND METHODS

Construction of directed deletion mutants. A megaprimer PCR method was employed to replace target genes in the genome of the *S. pneumoniae* TIGR4, D39, and SME215 strains with the spectinomycin-resistance cassette of plasmid pR412T7 (Bijlsma, J.J.E. et al, 2007, Appl. Environm. Microbiol. 73(5):1514-1524). In the first step, the spectinomycin resistance cassette and the two flanking regions of the target gene were PCR-amplified using plasmid pR412T7 or chromosomal DNA isolated from one of the three pneumococcal strains as template, respectively.

Flanking regions were about 500 bp in length and contained less than 150 bp of the coding sequence of the target gene. For each flanking region, the primer closest to the target gene contained an additional sequence complementary to a spectinomycin-cassette primer. In the second step, the PCR products of the two flanking regions were fused to the spectinomycin-resistance cassette by means of overlap extension PCR, leading to incorporation of the spectinomycin resistance cassette between the two flanking regions of the target gene. The resulting PCR product was transformed into the corresponding strain as follows.

First, precompetent *S. pneumoniae* cell stocks were prepared. Briefly, cCAT medium (10 g liter⁻¹ Casamino Acids (Difco), 5 g liter⁻¹ tryptone (Difco), 10 g liter⁻¹ yeast extract (Difco), 5 g liter⁻¹ NaCl, 16 mM K₂PO₄, 0.2% glucose, and 0.15 g liter⁻¹ glutamine) was inoculated with several colonies and grown to an optical density at 620 nm (OD620) of 0.25-0.3. After a 30-fold dilution of the culture in CTM medium (cCAT medium supplemented with 0.2% bovine serum albumin and 1 mM CaCl₂), cells were grown to an OD620 of 0.1, pelleted, resuspended in 0.1 volume of CTM-pH7.8 (CTM adjusted to pH 7.8 with NaOH) containing 15% glycerol, and stored at -80°C.

For transformation, precompetent TIGR4, D39, or SME215 cells were grown for 15 minutes at 37°C in a 10-fold volume of CTM-pH7.8 supplemented with 100 ng/ml CSP (CSP-1 for D39 and SME215, CSP-2 for TIGR4). After addition of DNA, cultures were incubated for 30 min at 32°C, followed by a two-hour incubation at 37°C. After overnight growth on selective plates containing 150 μg/ml spectinomycin, single transformants were picked from the plates, pooled, grown to mid-log phase in 20 ml of GM17 medium supplemented with spectinomycin, and stored at -80°C.
Transformants were selected on the basis of spectinomycin-resistance and were checked by PCR for recombination at the desired location on the chromosome. In addition, a double mutant ASP1298ASP2205 was generated in each of the three pneumococcal strains. To this end, the SP1298 gene was inactivated by allelic replacement with a trimethoprim cassette as described above, and introduced into the respective ASP2205 strains (spectinomycin) by transformation.

**Plasmid construction and production of His-tagged SP1298.** The SP1298 gene of the *S. pneumoniae* TIGR4 strain was PCR-amplified with LCSP1298XbalH6F and LCSP1298BamR oligonucleotide primer pairs and cloned into the pCR2.1 cloning vector of the TA cloning kit (Invitrogen) to obtain pLC1298. In the next step, the SP1298 gene was excised by Xbal and BamHI digestion and then subcloned into the expression plasmid vector pETllc (Novagen) to obtain pLC1298Xbal

For production of His-tagged SP21298, overnight cultures of *E. coli* BL21 (pLC1298Xbal

(pLC1298Xbal

In the next step, the SP1298 gene was excised by Xbal and BamHI digestion and then subcloned into the expression plasmid vector pETllc (Novagen) to obtain pLC1298Xbal

**Plasmid construction and production of His-tagged SP2205.** The SP2205 gene of the *S. pneumoniae* TIGR4 strain was PCR-amplified with LCSP2205AvrH6F and LCSP2205BamR and cloned into the pCR2.1 cloning vector of the TA cloning kit (Invitrogen) to obtain pLC2205. In the next step, the SP2205 gene was excised by BamHI and Avrl digestion and subsequently subcloned into the expression plasmid vector pETllc (Novagen) to obtain pLC2205_6. The nucleotide sequence of the cloned SP2205 gene was confirmed by sequencing.
For production of His-tagged SP2205, overnight cultures of *E. coli* BL21 (pLC2205_6) were 50-fold diluted in prewarmed (37°C) 2x LB supplemented with 0.5% glucose and 100 µg/ml ampicillin. At an OD600 between 0.6 and 0.8, IPTG was added to a final concentration of 0.1 mM. After 2 hrs, cells were pelleted, resuspended in lysis buffer (20mM sodium phosphate, 0.5 M sodium chloride, pH 7.4, 10mM Imidazole, 6M urea, 1mM PMSF, and 10% Triton-X-100) to OD600 equivalent to 100. Before sonication, 100mM PMSF, 100mM BZA, and lysozyme was added to the SP2205 pellet to improve lysis. Any additional insoluble debris in the lysate was removed by ultracentrifugation at 40,000 rpm for 60 min. The resulting supernatant was loaded onto a 1 ml HiTrap Chelating HP column (Amersham Biosciences) with Nickel for purification and eluted with 300mM Imidazole. Fractions containing SP2205 were dialyzed against 100mM Hepes, 6M urea, and 0.1% Triton-X 100. After dialysis, rHisSP2205 was stored in solution at −20°C until further use. The identity of the purified protein was confirmed by MALDI-TOF analysis and the concentration was determined by the bicinchoninic acid assay (Bio-Rad).

**Cell line and cell culture.** The human pharyngeal epithelial cell line Detroit 562 (ATCC number CCL-138) was routinely grown in RPMI 1640 medium without phenol red (Invitrogen, The Netherlands) supplemented with 1 mM sodium pyruvate and 10% (v/v) fetal calf serum (FCS). All cells were cultured at 37°C in a 5% CO2 environment.

**Adherence assay.** For adherence assays, bacteria were grown to mid-exponential phase in THY and stored in 1-ml aliquots at -80°C in THY containing 15% glycerol. Before each assay, bacteria were resuspended in RPMI 1640 medium without phenol red supplemented with 1% FCS. Adherence of pneumococci to epithelial cells was performed as described previously (Bootsma H.J. et al., 2007, Infect. Immun. 75:5489-5499; Hermans P.W.M. et al, 2006, J. Biol. Chem. 281(2):968-976). Briefly, Detroit 562 cells were seeded into 24-well plates and incubated for 48 h. Confluent monolayers were washed twice with PBS and infected with 1x10⁷ CFU ml⁻¹ (multiplicity of infection (MOI) of 10 (bacteria/cells)) and pneumococci were allowed to adhere to the cells for 2 h at 37°C in a 5% CO2 environment. Non-adherent bacteria were removed by three 1-ml washes with PBS, after which 200 µl of 25% trypsin, 1 mM EDTA was added to detach the cells, followed by 800 µl of ice-cold 0.025% Triton X-100 in PBS to lyse the cells. Samples were plated for CFU count, and corrected to
account for small differences in the initial inoculum count. All experiments were performed in triplicate and repeated at least three times. The adherence of the mutants is given as the percentage relative to the wild-type. Wild-type and mutant strains grew comparably in RPMI medium (without phenol red supplemented with 1% FCS) alone.

**In vivo virulence studies.** Eight-week old female outbred CD-I mice (Charles River Laboratories) were used for all infection models. Aliquots of bacteria stored at \(-80\, ^\circ\text{C}\) were rapidly thawed, harvested by centrifugation, and resuspended in sterile PBS to give the required amount of CFU/ml. Prior to infection, strains were passaged in mice to maintain virulence as described previously (Hendriksen W.T. et al., 2007, J. Bacteriol. 189:1382-1389). For the pneumonia model, mice were lightly anesthetized with 2.5% (vol/vol) isoflurane / \(\text{O}_2\), and infected intranasally by pipetting 50 \(\mu\text{l}\) of inoculum (5\(\times\)10⁸ CFU total) onto the nostrils of mice held in an upright position. At predetermined times after infection, groups of mice were sacrificed by injection anesthesia, and blood samples were removed by retro-orbital bleeding. Bacteria were recovered from the nasopharynx by flushing the nostrils with 2 ml sterile PBS (nasopharyngeal lavage, NPL). Bronchoalveolar lung lavage (BAL) was performed by flushing the lungs with 2 ml sterile PBS, after which lungs were removed from the body and homogenized in 2 ml of sterile PBS using a hand held homogenizer. In the colonization model, mice were infected intranasally with 10 \(\mu\text{l}\) of inoculum (5\(\times\)10⁸ CFU total), a volume small enough to only infect the nose (nasopharynx) of the mice. At predetermined time-points after infection, NPL and lung were collected as described above. In the bacteremia model, mice were infected in a tail vein with a 100-\(\mu\text{l}\) inoculum (10⁶-10⁷ CFU total). Bacteria were recovered from the blood by a lateral tail vein puncture from the same mouse at 0, 12, 24 and 36 hours post-infection. The number of viable bacteria in NPL, BAL, blood and homogenized lungs was determined by plating serial 10-fold dilutions on blood agar (BA) plates.

For all co-infection experiments, a 1:1 ratio of wild-type and mutant was used to infect the mice as described in the above mentioned models. This set-up reduces variation between individual mice, inoculation preparation and distribution, and sample collection. Viable bacteria were quantified by plating serial dilutions on BA plates and BA plates supplemented with either spectinomycin or spectinomycin and trimethoprim. Subsequently, competitive index (CI) scores were calculated for each
individual animal as the output ratio of mutant to wild type divided by the input ratio of mutant to wild type bacteria. For all experiments in which no mutant bacteria were recovered from a particular mouse, the number 20 (lower limit of detection) was substituted as the numerator. A log CI score of 0 indicates equal numbers of wild-type and mutant bacteria, a CI score <0 indicates that the mutant is outcompeted by the wild-type. All animal experiments were performed with approval of the Radboud University Nijmegen Medical Centre Committee for Animal Ethics.

**Vaccination study.** Female CD-I mice (6 weeks old) were subcutaneously immunized with 150 µl of vaccine or control (alum was used as the negative control and Prevenar as the positive). Aluminum hydroxide gel (Sigma) was the adjuvant used and was formulated with each of the vaccines at 3mg/ml. Complete immunizations consisted of three doses at 14-day intervals. Each group consisted of 10 mice. Singly vaccinated mice were given 50µg of antigen and the mice receiving a combination of both DHH proteins received 25µg of each. Mice were challenged with the TIGR4WT strain two and a half weeks after the last immunization in our pneumonia model and sampled 48 hours post-infection.

**Detection of antigen-specific IgG by ELISA.** To determine the concentrations of antibodies against SP1298, SP2205, SP1298/SP2205, an ELISA procedure was used. High binding capacity microtitre plates (Greiner, Alphen aan de Rijn, The Netherlands) were coated with 1µg/µl purified rHisSP1298 or rHisSP2205 in 100 µl/well overnight at 4°C. Plates were washed with PBS (pH 7.4) with 0.05% Tween 20, then incubated 1 h with 2% BSA in PBS/Tween. Three-fold dilutions of sera were added to the plates and incubated for 1 h at 37°C. After washing, the alkaline phosphatase secondary antibody directed to mouse IgG-Fc (Sigma-Aldrich) was incubated for 1 h at 37°C using a 1:25000 dilution. After washing with 0.05% Tween 20, 100 µl/well of p-nitrophenyl phosphate in substrate buffer (10mM diethanolamine and 0.5mM magnesium chloride, pH 9.5) was added and read at 405nm.

**Statistical analyses.** Comparisons of bacterial loads between wild-type and mutant bacterial strains were performed using Student's t-test (unpaired) for *in vitro* adherence and with the single mouse infection models. For the co-infection, comparison of log CI scores was performed using the one-sample t-test (with an
arbitrary median of 0) with $P < 0.05$ considered statistically significant. All statistical analyses were performed using GraphPad Prism version 4.0.

**RESULTS**

From Fig. 2 it appears that adherence to pharyngeal epithelial cells was impaired in the SP1298 and in the SP2205 mutants when compared to their respective wild types (either TIGR4, D39 or SME215). Deletion of SP2205 showed the most dramatic effect in all three backgrounds, all being highly significant. The SP1298 mutant showed a significant decrease in adherence in the SME215 background, and a trend towards decrease in the other two strains.

With respect to the infection studies, in the colonization model, a significant reduction in bacterial load in both single and co-infection setup was observed for both single mutants and the double mutant (Fig. 3), especially in the TIGR4 background. No synergistic or additive effect was observed when comparing the single mutants with the double mutant, except for the D39 background, where the double mutant was considerably more outcompeted than the two single mutants. In the pneumonia model (see Fig. 4) all mutants were significantly attenuated in the lungs in all three strains, both singly and in competition with their respective wild types. In the bacteremia infection model (Fig. 5) the SP2205 mutant in TIGR4 and D39 was only attenuated in blood in a co-infection setup, suggesting that this mutant is only able to efficiently survive during bacteremia when it is not in competition with wild type. The SP1298 mutant was significantly attenuated in blood of TIGR4 and D39 during both single and co-infection.

In the vaccination study, mice were injected with either one or both recombinant proteins. As is evident from Fig. 5, only a combination of both proteins provided protection against subsequent challenge with *S. pneumoniae* strain TIGR4, as bacterial loads were significantly lower in the lungs and blood of these mice compared to the negative control group that received adjuvant (alum) only. As compared to the positive control (the commercially obtainable vaccine Prevenar™) the combination performed nearly as well, while the individual results of the two proteins were less pronounced or absent.
It is thus submitted that the combination of SP2205 and SP1298 is a promising vaccine composition, which confers significant protection against pneumococcal pneumonia, also indicating that both SP1298 and SP2205 could be considered as potential candidates for a multi-component protein vaccine.
References


16 Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H.
Claims

1. An immunogenic composition or vaccine composition comprising protein SP1298 of *S. pneumoniae* and/or an immunogenic fragment thereof and/or a protein having an identity of more than 70% or protein fragment thereof for the treatment of microbial infections.

2. An immunogenic composition or vaccine composition comprising protein SP2205 of *S. pneumoniae* and/or an immunogenic fragment thereof and/or a protein having an identity of more than 70% or protein fragment thereof for the treatment of microbial infections.

3. An immunogenic composition or vaccine composition comprising protein SP1298 and protein SP2205 of *S. pneumoniae* and/or an immunogenic fragment(s) thereof and/or protein(s) having an identity of more than 70% with either SP1298 or SP2205 or protein fragment(s) thereof for the treatment of microbial infections.

4. A vaccine composition according to any of claims 1-3, additionally comprising a pharmaceutically acceptable carrier.

5. A vaccine composition according to any of claims 1-3, additionally comprising an adjuvant.

6. A vaccine composition according to any one of claims 1-5, wherein said formulation provides protections against pneumonia, meningitis, otitis media and/or sepsis caused by *Streptococcus pneumoniae*.

7. A method for prophylactic or therapeutic treatment of a pneumococcal infection in a subject comprising administering to a subject in need of such treatment an effective amount of a vaccine composition as defined in any one of claims 1-6.

8. A method for preparing an pneumococcal vaccine formulation, wherein said method comprises bringing into association, an effective amount of an SP1298 and SP2205 protein encoded or a functional fragment thereof and at least one of a pharmaceutically acceptable diluent, carrier, excipient or adjuvant therefore.

9. Use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of *S. pneumoniae* for
the preparation of a vaccine for the treatment or prophylaxis of a *S. pneumoniae* infection.

10. Use of a combination of SP1298 and SP2205 proteins or functional fragments thereof or homologous proteins or protein fragments thereof of *S. pneumoniae* for the preparation of a medicament for the treatment of diseases connected with *S. pneumoniae* infections.
Fig. 1

**SP1298**

1 BEICQQILEK IKEYDTIIHH RHMKPD PDAL GSQVGLKALL EHHFPEKTIK 50  
51 AVGFDDEPTLT WMAEMDLVED RAYQGALVIV CDTANTARID DRKYSQGDFL 100  
101 IKIDHHBNDD VYGDLSWVDT SSSASEMIT LFAQTQTQLAL ADROAEELLFA 150  
151 GIVGDTRGFL YPSITARTLR LAAYLREHNF DFAALTRKMD TMSYKIACLQ 200  
201 GYIYDHLEVQ ENGAARVILS QKILQYNIT DAETAAIVGA PGRIDRVS LW 250  
251 GIFVEQADGH YRVRLRSKVH PINEIAKEHD GGGHPASGA NSYSLEENEI 300  
301 IYQKLNLLK N

**SP2205**

1 mkkfyvspif pilvgliafg vlatfiifvn nniltvilif lvfvggyvfllf 50  
51 KKLRVHYTRS DVEQIQYVNHH QAEESLTALL EQMPVGVMKL NLSSGEVEWF 100  
101 NPYAELILT K EDGDFDLEAV QTIIKASVGN PSTYKLGEK RYAVHMDASS 150  
151 GVLYFVDVSR EQAITDEVLTV SRPVGIGVSV DNYDDLED ET SESDISQINS 200  
201 FVANFISEFS EKHHMFSSR RV SMDFYLFTD YTIVLEMNMND KFSVIDAFRE 250  
251 ESKQRQLPLT LSMGFSYGDG NHDEIGKVAL LNINLAEVRG GDQVVKEND 300  
301 ETKNPVPYFG GSAASIKRTR TRTRAMMTAI SDKIRSVDQ V FVVGHKNDLM 350  
351 DALGSAVGMO LFASNVIENS YALYDEEQMS PDIERAVSFI EKEGVTKLIS 400  
401 VKDAMGMVTN RSSLILVDHS KTLALTSKEF YDLFTQTIVI DHHHRRDQQDFP 450  
451 DNAVIT EIES GASSASELV ETBIFIQFNSK N NRLSRMQASV LMAGMLDLDTK 500  
501 NFSTSRVTSR FDVASYLRERGSDSIAIQEI AATDFEERYRE VNELILQGRK 550  
551 LGSDLVIAEA KDMCQDYTVV ISKAADMLA MSGIEASFVL AKNTQGFISI 600  
601 SARSRSKLNQVRIMEELGGG GHFNLAAQI KDVTLSEAGE KLTEIVLNEM 650  
651 KEKEKEE
Fig. 2

![Bar chart showing adherence of different strains relative to wild type.](image)
Fig. 3

**Single Infection**

**Co-Infection**

- **TIGR4 strain**
- **D39 strain**
- **SME215 strain**

Time post-infection (h) vs. LOG (CFU/ml) for each strain under different conditions.
Fig. 4

Single Infection

TIGR4 strain

D39 strain

SME215 strain

Co-Infection

Log (CFU/ml)

Time post-infection (h)

Log (C Score)
Fig. 5

Single Infection

Co-Infection
Fig. 6

Challenge with TIGR4WT

Lung

Lung Lavage

Blood

Nose Lavage
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/09 A61P31/04 C07K14/315

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, Sequence Search, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.

X CRON ET AL: "Contribution of DHH Subfamily 1 Proteins to Pneumococcal Virulence" ANTONIE VAN LEEUWENHOEK, vol. 95, 0077, 1 April 2009 (2009-04-01), pages 43-43, XP002589669 D01:
10.100/s 10482-009-9328-5 abstract 1,2, 4-7

X W0 02/077021 A2 (CHIRON SPA [IT]; INST GENOMIC RESEARCH [US]; MASIGNANI VEGA [IT]; TETT) 3 October 2002 (2002-10-03) sequence 2616

X W0 2008/146164 A2 (NOVARTIS AG [CH]; DONATI CLAUDIO [IT]; MASIGNANI VEGA [IT]; MORA MARIR) 4 December 2008 (2008-12-04) page 155; sequence 1107

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

A" document defining the general state of the art which is not considered to be of particular relevance
E" earlier document but published on or after the international filing date
L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document
O" document referring to an oral disclosure, use, exhibition or other means
P" document published prior to the international filing date but later than the priority date claimed

T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A' document member of the same patent family

Date of the actual completion of the international search
30 June 2010

Date of mailing of the international search report
28/07/2010

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer
Wagner, Rene
<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>LEUZZI ET AL: &quot;Genome mining and reverse vaccinology&quot;</td>
<td>1-10</td>
</tr>
<tr>
<td></td>
<td>1 January 2006 (2006-01-01), HANDBOOK OF MENINGOCOCCAL DISEASE, PAGE(S) 391 - 402</td>
<td></td>
</tr>
<tr>
<td></td>
<td>XP009116802</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td></td>
</tr>
</tbody>
</table>

Form PCT/ISA210 (continuation of second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 02077021 A2</td>
<td>03-10-2002</td>
<td>AU 2002309130 A1</td>
<td>08-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2439431 A1</td>
<td>03-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EF 1373513 A2</td>
<td>02-01-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005503119 T</td>
<td>03-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009213466 A</td>
<td>24-09-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005020813 A1</td>
<td>27-01-2005</td>
</tr>
<tr>
<td>WO 2008146164 A2</td>
<td>04-12-2008</td>
<td>AU 2008256340 A1</td>
<td>04-12-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2688284 A1</td>
<td>04-12-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2167531 A2</td>
<td>31-03-2010</td>
</tr>
</tbody>
</table>